BCR-ABL Monitoring

Chronic Myeloid Leukemia (CML) is a type of blood cancer with a good prognosis due to effective treatments.¹ Once on appropriate therapy, guidelines recommend all patients require molecular monitoring on a regular basis.² Sensitive and standardised PCR testing with the GeneXpert® system provides accurate, on-demand, and actionable results for improved patient management. That’s the PCRplus advantage.

Challenge

Complex Testing Workflow, Including Requiring Alignment to the
International Scale (IS) for an Increasing Number of Patients²

Solution

Easy-to-Use, Sensitive and Standardised Quantitative Monitoring
of BCR-ABL in Around 3 Hours

Learn More

1 Domenico R, et al. Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and Perspectives. J Clin Med. 2020 Jun 2;9(6):1709.

2 Hochhaus A, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Mar 34:966-84.

CE-IVD. In Vitro Diagnostic Medical Device. May not be available in all countries.